Brilinta contains ticagrelor as its active component. It belongs to the “Heart & Blood Pressure” therapeutic class and is available as an oral pill in 60 mg and 90 mg strengths. In Hong Kong, Brilinta is a prescription medicine regulated by the Department of Health under the Pharmacy and Poisons Ordinance.
Ticagrelor is a reversible P2Y12 receptor antagonist. By binding to the platelet P2Y12 ADP receptor, it blocks ADP-mediated platelet activation and aggregation. This inhibition reduces the formation of blood clots that can block coronary arteries. The drug has a rapid onset of action (within 30 minutes) and achieves maximal platelet inhibition in about 2 hours. Its effects last for the dosing interval because ticagrelor is not a pro-drug and does not require metabolic activation.
These indications are approved by the U.S. Food and Drug Administration (FDA) and are recognized by Hong Kong’s health authorities for patients who meet specific clinical criteria.
No robust peer-reviewed evidence currently supports off-label uses of ticagrelor. Clinicians may consider experimental applications only within clinical trials or under strict medical supervision.
Absolute contraindications
Known hypersensitivity to ticagrelor, any component of the pill, or other P2Y12 inhibitors.
Active pathological bleeding (e.g., intracranial hemorrhage, gastrointestinal bleeding).
Relative contraindications
Severe hepatic impairment (Child-Pugh C).
Concurrent use of strong CYP3A4 inhibitors (e.g., ketoconazole) - may increase ticagrelor levels.
Pregnancy or breastfeeding - safety not established; use only if benefits outweigh risks.
Special populations
Elderly patients may require careful monitoring for bleeding.
Patients with moderate renal impairment (creatinine clearance 30-59 mL/min) generally do not need dose adjustment but should be observed for adverse events.
Administration tips
Missed dose - Take the missed tablet as soon as remembered unless the next scheduled dose is within 2 hours, in which case skip the missed dose. Never double-dose.
Overdose - Symptoms may include severe bleeding, shortness of breath, or fainting. Seek emergency medical care; there is no specific antidote, but supportive measures and platelet transfusion may be used.
Discontinuation - Stopping ticagrelor abruptly increases the risk of thrombosis. A physician should guide any tapering or transition to alternative antiplatelet therapy.
This article provides educational information about Brilinta and is not a substitute for professional medical advice. Treatment decisions, including use for unapproved indications, must be made under the guidance of a qualified healthcare provider. The content is intended for informational purposes and does not constitute medical recommendations. Always consult a physician before starting, stopping, or changing any medication regimen.
Brilinta (ticagrelor) is a reversible P2Y12 inhibitor with a faster onset and more consistent platelet inhibition than clopidogrel, which is an irreversible pro-drug requiring metabolic activation. This pharmacologic distinction can influence bleeding risk and effectiveness in acute coronary syndrome.
Dyspnea is a common side effect of ticagrelor; patients with underlying respiratory disease should discuss the risk-benefit balance with their clinician, but asthma is not an absolute contraindication.
Ticagrelor does not require dose adjustment for mild to moderate renal impairment, but severe renal disease (creatinine clearance <30 mL/min) warrants careful monitoring for bleeding.
Keep the medication in its original container, protected from heat and humidity. In hot climates, store the bottle in a temperature-controlled bag and avoid leaving it in a parked car.
Ticagrelor does not interfere with lipid panels. However, any blood draw should be coordinated with your clinician to ensure appropriate timing relative to your antiplatelet therapy.
Transitioning between antiplatelet drugs should be guided by a physician. Typically, ticagrelor is stopped and another agent is started after a brief gap to minimize overlapping antithrombotic effects.
Vision disturbances are not a recognized side effect of ticagrelor. New visual symptoms should be evaluated promptly as they may indicate bleeding or other unrelated conditions.
Take the missed tablet as soon as you remember, unless the next scheduled dose is within two hours. In that case, skip the missed dose and continue with the regular schedule; do not double the dose.
Some herbs (e.g., St. John’s wort) induce CYP3A4 and may reduce ticagrelor effectiveness, while others like ginkgo biloba could increase bleeding risk. Inform your healthcare provider of all supplements you take.
Coverage depends on the specific plan and clinical indication. Patients should verify eligibility with their insurer or the Hospital Authority’s formulary list.
